Solit, David

Publications

Sort by

Co-Author Network

selected publications

A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. Cancer. 2020 Academic Article GET IT
Times cited: 10
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. European urology. 2020 Academic Article GET IT
Times cited: 16
Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. Cancer. 2020 Academic Article GET IT
Times cited: 3
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. The Lancet. Oncology. 2020 Academic Article GET IT
Times cited: 188
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 38
Fragment Size Analysis May Distinguish Clonal Hematopoiesis from Tumor-Derived Mutations in Cell-Free DNA. Clinical chemistry. 2020 Letter GET IT
Times cited: 23
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 79
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer discovery. 2020 Academic Article GET IT
Times cited: 100
Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. Cancer. 2020 Academic Article GET IT
Times cited: 20
Author Correction: Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2020 Academic Article GET IT
Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA oncology. 2020 Academic Article GET IT
Times cited: 49
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. The oncologist. 2019 Academic Article GET IT
Times cited: 9
Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019 Academic Article GET IT
Times cited: 221
Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 10
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer discovery. 2018 Academic Article GET IT
Times cited: 98
Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. Cancer. 2018 Academic Article GET IT
Times cited: 34
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 290
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 130
Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 34
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2018 Academic Article GET IT
Times cited: 14
Genome doubling shapes the evolution and prognosis of advanced cancers. Nature genetics. 2018 Academic Article GET IT
Times cited: 268
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 300
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 83
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 276
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 94
Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of surgical oncology. 2018 Academic Article GET IT
Times cited: 14
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell. 2018 Academic Article GET IT
Times cited: 438
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 164
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 343
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 882
Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer discovery. 2017 Academic Article GET IT
Times cited: 191
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science (New York, N.Y.). 2017 Academic Article GET IT
Times cited: 627
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 67
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer discovery. 2017 Academic Article GET IT
Times cited: 214
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 236
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017 Academic Article GET IT
Times cited: 289
Oncologist use and perception of large panel next-generation tumor sequencing. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 28
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell stem cell. 2017 Academic Article GET IT
Times cited: 435
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 137
AKT Inhibition in Solid Tumors With AKT1 Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 193
PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. Oncotarget. 2017 Academic Article GET IT
Times cited: 28
Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin. Cancer cytopathology. 2017 Academic Article GET IT
Times cited: 24
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer discovery. 2017 Academic Article GET IT
Times cited: 399
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 149
The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. JAMA oncology. 2017 Academic Article GET IT
Times cited: 158
Gene Signature Associated with Upregulation of the Wnt/β-Catenin Signaling Pathway Predicts Tumor Response to Transarterial Embolization. Journal of vascular and interventional radiology : JVIR. 2017 Academic Article GET IT
Times cited: 10
3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets. Genome medicine. 2017 Academic Article GET IT
Times cited: 134
ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. Cancer research. 2017 Academic Article GET IT
Times cited: 14
Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. Cancer. 2016 Academic Article GET IT
Times cited: 33
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 121
Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer. 2016 Academic Article GET IT
Times cited: 46
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England journal of medicine. 2016 Academic Article GET IT
Times cited: 1009
Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. European urology. 2016 Academic Article GET IT
Times cited: 56
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 222
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 135
Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 128
Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. Pediatric blood & cancer. 2016 Academic Article GET IT
Times cited: 27
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Science signaling. 2016 Academic Article GET IT
Times cited: 50
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 175
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature genetics. 2016 Academic Article GET IT
Times cited: 118
Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. The Journal of pathology. 2016 Academic Article GET IT
Times cited: 89
Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. The Journal of urology. 2016 Academic Article GET IT
Times cited: 32
Reply to M.P. Decatris et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Letter GET IT
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA oncology. 2016 Academic Article GET IT
Times cited: 216
Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular cancer research : MCR. 2015 Academic Article GET IT
Times cited: 37
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nature biotechnology. 2015 Academic Article GET IT
Times cited: 509
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer discovery. 2015 Academic Article GET IT
Times cited: 313
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer cell. 2015 Academic Article GET IT
Times cited: 307
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. 2015 GET IT
Times cited: 76
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug discovery today. 2015 Academic Article GET IT
Times cited: 121
Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells. eLife. 2015 Academic Article GET IT
Times cited: 66
Genomic Characterization of Upper Tract Urothelial Carcinoma. European urology. 2015 Academic Article GET IT
Times cited: 165
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 3
Tumor Genetic Screening Programs: A Call to Action. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Editorial Article GET IT
Times cited: 13
Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PloS one. 2015 Academic Article GET IT
Times cited: 33
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. The oncologist. 2015 Academic Article GET IT
Times cited: 54
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 2014 Academic Article GET IT
Times cited: 134
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature. 2014 Academic Article GET IT
Times cited: 396
Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged. Cancer cell. 2014 Academic Article GET IT
Times cited: 42
MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 104
Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. Clinical colorectal cancer. 2014 Academic Article GET IT
Times cited: 30
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome biology. 2014 Academic Article GET IT
Times cited: 259
Realizing the potential of plasma genotyping in an age of genotype-directed therapies. Journal of the National Cancer Institute. 2014 Academic Article GET IT
Times cited: 35
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer discovery. 2014 Academic Article GET IT
Times cited: 438
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. European urology. 2014 Academic Article GET IT
Times cited: 110
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer discovery. 2014 Academic Article GET IT
Times cited: 97
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 79
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014 Academic Article GET IT
Times cited: 146
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. 2014 GET IT
Times cited: 67
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer research. 2014 Academic Article GET IT
Times cited: 228
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 81
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014 Academic Article GET IT
Times cited: 2179
Towards a unified model of RAF inhibitor resistance. Cancer discovery. 2014 Academic Article GET IT
Times cited: 35
Perturbation biology: inferring signaling networks in cellular systems. PLoS computational biology. 2013 Academic Article GET IT
Times cited: 96
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nuclear medicine communications. 2013 Academic Article GET IT
Times cited: 61
Tumor adaptation and resistance to RAF inhibitors. Nature medicine. 2013 Review GET IT
Times cited: 430
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 240
ERK pathway inhibitors: how low should we go?. Cancer discovery. 2013 Academic Article GET IT
Times cited: 41
Phase II study of everolimus in metastatic urothelial cancer. BJU international. 2013 Academic Article GET IT
Times cited: 144
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 111
Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. Cancer research. 2013 Academic Article GET IT
Times cited: 71
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature genetics. 2013 Academic Article GET IT
Times cited: 265
Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. Cancer discovery. 2012 Academic Article GET IT
Times cited: 52
Progression of RAS-mutant leukemia during RAF inhibitor treatment. 2012 GET IT
Times cited: 197
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2012 Academic Article GET IT
Times cited: 147
Genome sequencing identifies a basis for everolimus sensitivity. Science (New York, N.Y.). 2012 Academic Article GET IT
Times cited: 578
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Academic Article GET IT
Times cited: 1400
Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012 Academic Article GET IT
Times cited: 6108
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. 2012 GET IT
Times cited: 175
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. Journal of pharmacokinetics and pharmacodynamics. 2012 Academic Article GET IT
Times cited: 11
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012 Academic Article GET IT
Times cited: 1433
Comparative genomic analysis of primary versus metastatic colorectal carcinomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 225
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. Cancer chemotherapy and pharmacology. 2012 Academic Article GET IT
Times cited: 2
Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Comment GET IT
Times cited: 13
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer. 2012 Academic Article GET IT
Times cited: 55
Translational medicine: Primed for resistance. Nature. 2012 Comment GET IT
Times cited: 11
Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imaging. Molecular imaging. 2012 Academic Article GET IT
Times cited: 12
12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report. Urologic oncology. 2012 Conference Paper GET IT
Times cited: 3
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer discovery. 2012 Academic Article GET IT
Times cited: 90
Targeting oncogenic BRAF in human cancer. Current topics in microbiology and immunology. 2012 Academic Article GET IT
Times cited: 32
The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?. Current oncology reports. 2011 Review GET IT
Times cited: 28
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 28
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Academic Article GET IT
Times cited: 1143
Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Comment GET IT
Times cited: 50
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clinical colorectal cancer. 2011 Academic Article GET IT
Times cited: 60
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature genetics. 2011 Academic Article GET IT
Times cited: 254
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene. 2011 Academic Article GET IT
Times cited: 159
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 347
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. The Journal of pathology. 2011 Academic Article GET IT
Times cited: 71
Resistance to MEK inhibitors: should we co-target upstream?. Science signaling. 2011 Review GET IT
Times cited: 105
Resistance to BRAF inhibition in melanomas. The New England journal of medicine. 2011 Academic Article GET IT
Times cited: 197
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 34
Drug discovery: How melanomas bypass new therapy. Nature. 2010 Comment GET IT
Times cited: 43
Oncogenic RAF: a brief history of time. Pigment cell & melanoma research. 2010 Academic Article GET IT
Times cited: 9
KRAS and BRAF: drug targets and predictive biomarkers. The Journal of pathology. 2010 Review GET IT
Times cited: 132
Tracing cancer networks with phosphoproteomics. Nature biotechnology. 2010 Academic Article GET IT
Times cited: 14
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 121
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer research. 2010 Academic Article GET IT
Times cited: 135
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 374
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer cell. 2010 Academic Article GET IT
Times cited: 326
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer research. 2010 Academic Article GET IT
Times cited: 229
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Review GET IT
Times cited: 147
The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E. Cell cycle (Georgetown, Tex.). 2010 Editorial Article GET IT
Times cited: 27
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer research. 2010 Academic Article GET IT
Times cited: 194
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nature genetics. 2009 Academic Article GET IT
Times cited: 299
Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magnetic resonance in medicine. 2009 Academic Article GET IT
Times cited: 17
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene. 2009 Academic Article GET IT
Times cited: 99
PIK3CA mutation associates with improved outcome in breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 315
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer research. 2009 Academic Article GET IT
Times cited: 429
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 212
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 80
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 457
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 172
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 42
Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer research. 2008 Academic Article GET IT
Times cited: 214
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Molecular cancer therapeutics. 2008 Academic Article GET IT
Times cited: 110
Therapeutic strategies for inhibiting oncogenic BRAF signaling. Current opinion in pharmacology. 2008 Review GET IT
Times cited: 66
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer research. 2008 Academic Article GET IT
Times cited: 175
The current state of preclinical prostate cancer animal models. The Prostate. 2008 Academic Article GET IT
Times cited: 106
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. The Journal of clinical endocrinology and metabolism. 2008 Academic Article GET IT
Times cited: 110
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer research. 2008 Academic Article GET IT
Times cited: 157
Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nature biotechnology. 2008 Academic Article GET IT
Times cited: 97
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 158
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer research. 2007 Academic Article GET IT
Times cited: 60
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 311
Development and application of Hsp90 inhibitors. Drug discovery today. 2007 Review GET IT
Times cited: 226
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PloS one. 2007 Academic Article GET IT
Times cited: 101
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Cancer immunology, immunotherapy : CII. 2007 Academic Article GET IT
Times cited: 65
Therapeutic strategies for targeting BRAF in human cancer. Reviews on recent clinical trials. 2007 Review GET IT
Times cited: 37
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 13
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 189
Targeting HER2 in prostate cancer: where to next?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Editorial Article GET IT
Times cited: 32
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2006 Academic Article GET IT
Times cited: 48
Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer research. 2006 Academic Article GET IT
Times cited: 75
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Current opinion in investigational drugs (London, England : 2000). 2006 Review GET IT
Times cited: 91
Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2006 Academic Article GET IT
Times cited: 157
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer research. 2006 Academic Article GET IT
Times cited: 2180
Hsp90: a novel target for cancer therapy. Current topics in medicinal chemistry. 2006 Review GET IT
Times cited: 158
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 2005 Academic Article GET IT
Times cited: 257
BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2005 Academic Article GET IT
Times cited: 1155
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 110
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer cell. 2005 Academic Article GET IT
Times cited: 360
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 119
Induction of complete regressions of oncogene-induced breast tumors in mice. Cold Spring Harbor symposia on quantitative biology. 2005 Academic Article GET IT
Times cited: 8
Hsp90: the vulnerable chaperone. Drug discovery today. 2004 Review GET IT
Times cited: 196
New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target. Journal of the American Chemical Society. 2004 Academic Article GET IT
Times cited: 160
Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chemistry & biology. 2004 Academic Article GET IT
Times cited: 164
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nature biotechnology. 2004 Academic Article GET IT
Times cited: 289
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer. 2004 Academic Article GET IT
Times cited: 31
A role for Id proteins in mammary gland physiology and tumorigenesis. Advances in cancer research. 2004 Review GET IT
Times cited: 49
Generation of DOTA-conjugated antibody fragments for radioimmunoimaging. Methods in enzymology. 2004 Academic Article GET IT
Times cited: 17
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer research. 2003 Academic Article GET IT
Times cited: 62
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer. 2003 Academic Article GET IT
Times cited: 34
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proceedings of the National Academy of Sciences of the United States of America. 2003 Academic Article GET IT
Times cited: 86
Development of purine-scaffold small molecule inhibitors of Hsp90. Current cancer drug targets. 2003 Review GET IT
Times cited: 102
Hsp90 as a therapeutic target in prostate cancer. Seminars in oncology. 2003 Review GET IT
Times cited: 141
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Annals of oncology : official journal of the European Society for Medical Oncology. 2003 Academic Article GET IT
Times cited: 63
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 274
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer research. 2003 Academic Article GET IT
Times cited: 281
Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol. Angewandte Chemie (International ed. in English). 2003 Academic Article GET IT
Times cited: 77
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. The Journal of biological chemistry. 2002 Academic Article GET IT
Times cited: 547
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 435
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene. 2002 Academic Article GET IT
Times cited: 251
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 173
Posterior fossa: analysis of a popular technique for estimating the location in children with medulloblastoma. Radiology. 1995 Academic Article GET IT
Times cited: 9

more ...

less ...

Background

education and training

M.D., University of Pennsylvania School of Medicine 1995
B.A., University of Pennsylvania 1991

Contact

full name

David Solit

primary email

solitd@mskcc.org

VIVO Weill Cornell Medical College

David Solit Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email